A rat model presenting eosinophilia in the airways, lung eosinophil activation, and pulmonary hyperreactivity.
The aim of this study was to examine antigen-induced lung cell migration, eosinophil activation, and pulmonary reactivity of Wistar rats exposed to a new sensitization technique. The animals were sensitized with a single subcutaneous implant of a fragment of heat coagulated hen egg white and challenged 21 days later with an intratracheal injection of heat-aggregated ovalbumin (EWI). For comparison, another group of rats were sensitized by an intraperitoneal injection of ovalbumin in alum as adjuvant, with one booster on day 14 and challenge on day 21 post immunization (OVA/AL). Twenty-four hours after antigen challenge, the EWI group presented a higher number of eosinophils in the bronchoalveolar lavage (BAL) (4.85 +/- 1.43 x 10(6)) than the OVA/AL group (0.2 +/- 0.06 x 10(6)) or the control group, where the level of eosinophils were essentially undetectable. Levels of eosinophil peroxidase activity were increased in the cell-free BAL and homogenates of lung tissue in the EWI group (12.10 +/- 2.97 mg/mL and 36.14 +/- 7.21 ng/mg, respectively), but not in the OVA/AL group (4.83 +/- 1.4 ng/mL and 11.95 +/- 2.54 ng/mg, respectively), as compared with controls (5.16 +/- 1.65 ng/mL and 12.13 +/- 1.74 ng/mg, respectively). Thromboxane B2 levels were also increased in the BAL of EWI group (2.89 +/- 0.54 ng/mL) but not the OVA/AL group (1.13 +/- 0.23 ng/mL) as compared with controls (1.14 +/- 0.19 ng/mL). In contrast, the levels of prostaglandin E2 in the BAL were increased in both groups (456.4 +/- 11.8 pg/mL in the EWI group and 303.5 +/- 31.7 pg/mL in the OVA/AL group) as compared with controls (205.7 +/- 29.7 ng/mL). Moreover, only the EWI group developed increased pulmonary reactivity to serotonin (around two-fold), 24 hours after antigen challenge. The extent of lung eosinophil migration and activation and the pulmonary hyperreactivity induced by this novel sensitization procedure without adjuvants represents a significant improvement over existing experimental models of asthma.
Carvalho
C
C
Department of Pharmacology, Medical School, University of Sherbrooke, P.Q., Canada.
Jancar
S
S
Mariano
M
M
Sirois
P
P
D000818:Animals; D016535:Bronchial Hyperreactivity / Q000201:enzymology / Q000276:immunology*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D015232:Dinoprostone / Q000378:metabolism; D004195:Disease Models, Animal; D047209:Eosinophil Peroxidase; D004804:Eosinophils / Q000201:enzymology / Q000276:immunology*; D007114:Immunization / Q000379:methods; D010047:Ovalbumin / Q000276:immunology; D010544:Peroxidases / Q000378:metabolism; D011657:Pulmonary Eosinophilia / Q000201:enzymology / Q000276:immunology*; D051381:Rats; D017208:Rats, Wistar; D012129:Respiratory Function Tests; D012130:Respiratory Hypersensitivity / Q000201:enzymology / Q000276:immunology*; D012701:Serotonin / Q000494:pharmacology; D013929:Thromboxane B2 / Q000378:metabolism
D012701:Serotonin; D013929:Thromboxane B2; D010047:Ovalbumin; D047209:Eosinophil Peroxidase; D010544:Peroxidases; D015232:Dinoprostone